Revelation Biosciences regains Nasdaq compliance and advances PRIME Phase 1b CKD study

REVELATION BIOSCIENCES, INC.

Nasdaq confirmed REVB common stock meets minimum bid price and all continued listing requirements.
Company cannot use 180-day grace period if bid price falls below $1.00 again; would receive delisting letter but may request hearing.
PRIME Phase 1b study of Gemini IV in Stage 3-4 CKD patients has commenced, enrolling up to 40 patients across 5 cohorts.
CEO James Rolke highlighted Nasdaq listing for liquidity, capital access, and talent retention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.